Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. — Stella

Home/Immunoglobulin A Nephropathy/A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

View on ClinicalTrials.gov

Recruiting

Back to Immunoglobulin A Nephropathy trials

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Peking University First Hospital, Beijing

Key details

Phase

Early testing / Safety & dosing

Sponsor

Beijing Mabworks Biotech Co., Ltd.

Enrollment target

~130 participants

Started

February 2026

Primary completion

June 2028

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.